Zydus Cadila. the pharmaceutical firm, announced it had entered into an alliance for drug development and commercialization with Pieris AG. The two pharmaceutical firms would be collaborating to develop a new therapeutic protein molecule to be marketed as Anticalin.
The partnership would combine Pieris' drug discovery and development capabilities with Zydus' abilities in biologics development and manufacturing with regulatory affairs.
According to a joint statement from the companies, "Under the terms of agreement, Zydus will take the lead in advancing Anticalin drug candidates through preclinical development and into clinical development."
Under the terms of the agreement, Zydus would be given exclusive marketing rights in India and other emerging markets. On the other hand, Pieris would retain exclusive marketing rights in key developed markets.
According to Pieris CEO Stephen Yoder, "This collaboration will allow Pieris to unlock value on a global scale on a cost effective manner, signifcantly expanding the number of proprietary Anticalin programmes we can advance into clinical trials."
Join the Conversation